Novartis (NVS) Has a Potential $3 Billion MS Opportunity — But Investors Face Key Risks

Neha Gupta

Mon, September 7, 2026 at 9:03 PM GMT+3 4 min read

Novartis AG (NYSE:NVS) could be staring at a $3 billion annual peak-sales opportunity in multiple sclerosis (MS) if its drug remibrutinib successfully advances through the regulatory process and gains meaningful market share.

Bank of America estimates that remibrutinib could generate about $3 billion in peak annual sales in multiple sclerosis alone and potentially more than $10 billion across all indications.

Remibrutinib Delivers Encouraging MS Results

The comments follow Novartis AG (NYSE:NVS) receiving encouraging results from its REMODEL-1 and REMODEL-2 Phase 3 trials, announced on September 2. The trials evaluated remibrutinib in patients with relapsing multiple sclerosis. The results showed that remibrutinib reduced relapse activity and met the trials' primary endpoints. It also demonstrated reductions in inflammatory brain lesions compared with the active comparator and showed a favorable safety profile.

Novartis (NVS) Has a Potential $3 Billion MS Opportunity — But Investors Face Key Risks.

David Smart/Shutterstock.com

The results are important because they could strengthen Novartis' position in the rapidly evolving MS treatment market and potentially provide another growth engine alongside its established MS drug Kesimpta.

A Large and Growing MS Market

The opportunity is significant. The global multiple sclerosis therapeutics market is expected to grow at a 5.9% compound annual growth rate, reaching approximately $38.6 billion by 2030.

Novartis already has a major presence in the market through Kesimpta. The drug generated approximately $1.42 billion in second-quarter sales, up 32% year over year. The robust sales is attributed to strong global demand and favorable payer access.

Remibrutinib could therefore give Novartis another opportunity to expand its MS franchise rather than relying entirely on continued growth from Kesimpta.

Wall Street analysts are increasingly highlighting remibrutinib's commercial potential. Analysts at Citi estimate $3.2 billion in annual peak sales from the drug.

Kesimpta Growth Is Still Critical

Despite the promising pipeline, the pharmaceutical giant is not immune to underlying risks that could affect its performance. Maintaining robust Kesimpta sales could become increasingly difficult as the drug matures and competition intensifies.

The company will have to continue gaining market share and expand treatment penetration to sustain strong growth. A slowdown toward single-digit growth could reduce the drug's contribution to overall earnings growth.

Positive Phase 3 data are an important milestone, but they do not guarantee blockbuster sales. Management still needs to secure regulatory approvals and achieve significant physician adoption for the drug to drive bottom line growth.

Roche Adds Competitive Pressure

Competition is another major risk. Roche is developing a kinase (BTK) inhibitor targeting multiple sclerosis. The development of competing BTK therapies could limit remibrutinib's eventual market share and pricing power.

Hedge Fund Positioning and Short Interest

Institutional investors are maintaining significant interest in NVS stock as the company strengthens its pipeline.

According to Insider Monkey's database, 38 hedge funds held stakes in the company in the second quarter from 31 in the first quarter. During the quarter, Fisher Asset Management increased its position by 12% to approximately $2.43 billion, while GQG Partners reduced its stake by 13% to approximately $337.13 million.

Short interest, meanwhile, remains relatively low at approximately 0.26% of public float, or 4.99 million shares sold short. The low short interest indicates that relatively few investors are positioning for a significant decline in the stock.

The Verdict

Novartis' encouraging remibrutinib results strengthen the company's long-term MS growth story and could add billions of dollars in annual revenue if the drug secures regulatory approval and achieves successful commercialization. The bigger investment question, however, is how much of that opportunity is already reflected in Novartis' valuation.

Kesimpta provides Novartis AG (NYSE:NVS) with a strong existing MS franchise, while remibrutinib could offer another major growth driver. The broader pipeline adds further upside if multiple programs succeed. Overall, remibrutinib meaningfully improves Novartis' long-term growth potential.

While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None. Follow Insider Monkey on Google News.